ArQule, Inc.’s ARQL, -1.67% partner, Basilea Pharmaceutica Ltd. (six:BSLN), announced today that it entered into a collaboration with Roche (six:RO)(six:ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor,...
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 single-ascending...
The WVU Cancer Institute is enrolling patients in an innovative clinical trial to treat ovarian cancer. Valerie Galvan Turner, M.D., gynecologic oncologist at the WVU Cancer Institute, will help lead the trial to evaluate the efficacy of varying dosages and...
Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease (GVHD). The trial will evaluate the efficacy and safety of...
X-BOLT® Revolutionary Hip Fracture Device Granted FDA 510k Approval X-Bolt Orthopaedics, a leading medical device company, today announced the 1000th patient has completed one-year of follow-up in the (n= 1,140 patients) multi-centre randomised controlled trial...
Email
Text